KR20060012005A - 면역자극제 - Google Patents
면역자극제 Download PDFInfo
- Publication number
- KR20060012005A KR20060012005A KR1020057021797A KR20057021797A KR20060012005A KR 20060012005 A KR20060012005 A KR 20060012005A KR 1020057021797 A KR1020057021797 A KR 1020057021797A KR 20057021797 A KR20057021797 A KR 20057021797A KR 20060012005 A KR20060012005 A KR 20060012005A
- Authority
- KR
- South Korea
- Prior art keywords
- immunostimulant
- cpg
- modified
- cpg dna
- polysaccharide
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
- 면역자극성 올리고뉴클레오티드와 β-1,3-결합을 가지는 다당류의 복합체로 이루어지는 면역자극제.
- 제 1 항에 있어서, 면역자극성 올리고뉴클레오티드는, 비-메틸화 CpG 모티브를 포함하는 것을 특징으로 하는 면역자극제.
- 제 1 항에 있어서, 올리고뉴클레오티드의 인산 골격이, 포스포로티오에이트 또는 포스포로디티오에이트로 변형되어 있는 것을 특징으로 하는 면역자극제.
- 제 1 항에 있어서, β-1,3-결합을 가지는 다당류는 β-1,3-글루칸 또는 β-1,3-크실란인 것을 특징으로 하는 면역자극제.
- 제 4 항에 있어서, β-1,3-글루칸은 시조피란, 커드란(curdran), 레티난(lentinan), 파키만, 그리프론(grifron), 라미나란(laminaran) 또는 스클레로글루칸으로부터 선택되는 것을 특징으로 하는 면역자극제.
- 제 1 항에 있어서, 다당류가, 핵산결합성 및/또는 세포친화성 관능기로 변형되어 있는 것을 특징으로 하는 면역자극제.
- 제 1 항에 있어서, 올리고뉴클레오티드와 다당류와의 복합체는, 수소결합 및 소수성 상호작용을 통하여 형성되는 삼중 나선 구조인 것을 특징으로 하는 면역자극제.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003136876 | 2003-05-15 | ||
JPJP-P-2003-00136876 | 2003-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060012005A true KR20060012005A (ko) | 2006-02-06 |
KR100872472B1 KR100872472B1 (ko) | 2008-12-05 |
Family
ID=33447238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057021797A KR100872472B1 (ko) | 2003-05-15 | 2004-05-13 | 면역자극제 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7790189B2 (ko) |
EP (1) | EP1625850B1 (ko) |
JP (1) | JP4850512B2 (ko) |
KR (1) | KR100872472B1 (ko) |
CN (1) | CN1798563A (ko) |
AU (1) | AU2004238139B2 (ko) |
CA (1) | CA2527756C (ko) |
WO (1) | WO2004100965A1 (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO20014256D0 (no) | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Fremstilling av immunstimulerende forbindelse |
US7790189B2 (en) * | 2003-05-15 | 2010-09-07 | Mitsui Sugar Co., Ltd. | Immunostimulating agents |
EP1896600A2 (en) | 2005-06-15 | 2008-03-12 | Medimush A/S | Anti-cancer combination treatment and kit-of-part |
EP2227248B2 (en) * | 2007-11-26 | 2018-01-31 | GlaxoSmithKline Biologicals SA | Adjuvanted glucans |
WO2009068996A2 (en) | 2007-11-26 | 2009-06-04 | Novartis Ag | Conjugated beta-1,3-linked glucans |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
JPWO2012008465A1 (ja) * | 2010-07-16 | 2013-09-09 | ナパジェン ファーマ, インコーポレテッドNapaJen Pharma, Inc. | 核酸多糖複合体 |
KR102400963B1 (ko) | 2013-09-20 | 2022-05-24 | 고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 | 면역 부활 활성을 갖는 올리고뉴클레오티드 함유 복합체 및 그 용도 |
JP6383740B2 (ja) * | 2014-02-06 | 2018-08-29 | 国立研究開発法人科学技術振興機構 | ペプチド/β−1,3−グルカン複合体及びそれを含む医薬組成物 |
JP6501247B2 (ja) * | 2014-12-16 | 2019-04-17 | 公立大学法人北九州市立大学 | 免疫賦活用ポリヌクレオチド/シゾフィラン複合体及びそれを含む医薬組成物 |
CN106148266A (zh) * | 2015-04-20 | 2016-11-23 | 烟台赛泽生物技术有限公司 | 一种免疫细胞用培养基及该培养基的添加剂 |
CN105462922A (zh) * | 2015-12-31 | 2016-04-06 | 广州赛莱拉干细胞科技股份有限公司 | 一种增加免疫细胞得率的方法 |
EP3610880A4 (en) | 2017-03-23 | 2021-01-06 | Napajen Pharma, Inc. | CANCER CELL ADHESION ACTIVITY INHIBITOR |
CN107126558B (zh) * | 2017-04-26 | 2020-06-23 | 广州渔跃生物技术有限公司 | 鸡传染性法氏囊病灭活疫苗及其制备方法 |
CN108295049B (zh) * | 2018-02-12 | 2020-07-14 | 中山大学 | 一种负载抗原的水溶性胺化β-1,3-D-葡聚糖纳米粒子及其制备方法和应用 |
CN108553479A (zh) * | 2018-04-03 | 2018-09-21 | 南京大学 | 阳离子修饰的琼脂糖和核酸药物组合物及制备方法和应用 |
WO2022102694A1 (ja) | 2020-11-12 | 2022-05-19 | 第一三共株式会社 | 粒子径が制御された、ベータグルカンと核酸との複合体 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0468520A3 (en) * | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
JPH04352724A (ja) * | 1990-07-27 | 1992-12-07 | Mitsui Toatsu Chem Inc | 免疫調節型治療剤 |
US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
EP0721345B1 (en) * | 1993-08-11 | 2005-08-31 | Jenner Technologies | Prostatic cancer vaccine |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP1167379A3 (en) * | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1996014873A2 (en) * | 1994-11-16 | 1996-05-23 | Sri International | COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
AU726059B2 (en) * | 1996-04-19 | 2000-10-26 | Auburn University | Nucleic acid vaccination for parvoviral infections |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
EP0968226A4 (en) | 1996-12-27 | 2001-02-14 | Icn Pharmaceuticals | OLIGOAPTAMERS WITH G-ENRICHED REGIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
ES2326848T3 (es) | 1997-06-06 | 2009-10-20 | The Regents Of The University Of California | Inhibidores de la actividad de secuencias inmunoestimulatorias de adn. |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
ATE356630T1 (de) * | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
JP2002513763A (ja) * | 1998-05-06 | 2002-05-14 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Cpgオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法 |
DE69927495T2 (de) * | 1998-05-14 | 2006-07-06 | Coley Pharmaceutical Group, Inc., Wellesley | Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden |
US20010034330A1 (en) * | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
US5962636A (en) * | 1998-08-12 | 1999-10-05 | Amgen Canada Inc. | Peptides capable of modulating inflammatory heart disease |
WO2000020039A1 (en) | 1998-10-05 | 2000-04-13 | The Regents Of The University Of California | Methods and adjuvants for stimulating mucosal immunity |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
DE60022665T2 (de) | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
JP2003510290A (ja) * | 1999-09-27 | 2003-03-18 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激核酸誘導インターフェロンに関する方法 |
DE60038664T2 (de) * | 1999-11-10 | 2009-05-28 | Japan Science And Technology Agency, Kawaguchi | Genträger |
WO2001069173A1 (en) * | 2000-03-10 | 2001-09-20 | Spectra Precision Inc. | Versatile transmitter and receiver for position measurement |
WO2001093902A2 (en) * | 2000-06-07 | 2001-12-13 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
EP1369133B1 (en) | 2001-03-13 | 2012-08-01 | Japan Science and Technology Agency | Gene carriers comprising a beta-1,3-glucan and process for producing the same |
JP3594915B2 (ja) | 2001-08-03 | 2004-12-02 | 株式会社ナムコ | プログラム、情報記憶媒体及びゲーム装置 |
DE60234375D1 (de) * | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
US7537767B2 (en) * | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
US7790189B2 (en) * | 2003-05-15 | 2010-09-07 | Mitsui Sugar Co., Ltd. | Immunostimulating agents |
JP4712333B2 (ja) * | 2004-08-31 | 2011-06-29 | 独立行政法人科学技術振興機構 | ハイブリッド多糖系キャリアーを用いる核酸類の導入方法。 |
JP2007070307A (ja) * | 2005-09-09 | 2007-03-22 | Japan Science & Technology Agency | 免疫刺激性複合体 |
JP5473336B2 (ja) * | 2006-02-15 | 2014-04-16 | アディウタイド・ファーマスーティカルズ・ゲーエムベーハー | オリゴヌクレオチドの処方に関する組成物および方法 |
JP4878915B2 (ja) * | 2006-05-25 | 2012-02-15 | 独立行政法人科学技術振興機構 | 核酸/多糖/カーボンナノチューブ複合体 |
PL2034015T3 (pl) * | 2006-05-31 | 2012-11-30 | Toray Industries | Immunostymulujący oligonukleotyd i jego zastosowanie farmaceutyczne |
JP2008100919A (ja) * | 2006-10-17 | 2008-05-01 | Japan Science & Technology Agency | Th2細胞関連疾患の予防等に用いられる核酸/多糖複合体 |
WO2009068996A2 (en) * | 2007-11-26 | 2009-06-04 | Novartis Ag | Conjugated beta-1,3-linked glucans |
-
2004
- 2004-05-13 US US10/557,108 patent/US7790189B2/en active Active
- 2004-05-13 JP JP2005506241A patent/JP4850512B2/ja not_active Expired - Lifetime
- 2004-05-13 CA CA2527756A patent/CA2527756C/en not_active Expired - Fee Related
- 2004-05-13 CN CNA2004800132950A patent/CN1798563A/zh active Pending
- 2004-05-13 EP EP04732786A patent/EP1625850B1/en not_active Expired - Lifetime
- 2004-05-13 KR KR1020057021797A patent/KR100872472B1/ko active IP Right Grant
- 2004-05-13 WO PCT/JP2004/006793 patent/WO2004100965A1/ja active Application Filing
- 2004-05-13 AU AU2004238139A patent/AU2004238139B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
EP1625850A4 (en) | 2008-12-24 |
AU2004238139A1 (en) | 2004-11-25 |
CA2527756A1 (en) | 2004-11-25 |
EP1625850B1 (en) | 2012-02-29 |
EP1625850A1 (en) | 2006-02-15 |
US20080262210A1 (en) | 2008-10-23 |
JP4850512B2 (ja) | 2012-01-11 |
AU2004238139B2 (en) | 2009-12-03 |
CA2527756C (en) | 2014-05-06 |
JPWO2004100965A1 (ja) | 2006-07-13 |
US7790189B2 (en) | 2010-09-07 |
WO2004100965A1 (ja) | 2004-11-25 |
KR100872472B1 (ko) | 2008-12-05 |
CN1798563A (zh) | 2006-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100872472B1 (ko) | 면역자극제 | |
AU2021202301B2 (en) | Complex containing oligonucleotide having immunopotentiating activity and use thereof | |
JP6383740B2 (ja) | ペプチド/β−1,3−グルカン複合体及びそれを含む医薬組成物 | |
WO2016152767A1 (ja) | 免疫賦活活性を有するCpGスペーサーオリゴヌクレオチド含有複合体及びその用途 | |
WO2016098832A1 (ja) | ポリヌクレオチド/シゾフィラン複合体及びそれを含む医薬組成物 | |
JP7184366B2 (ja) | 免疫誘導剤及びそれを含む医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121018 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131112 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141105 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151105 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161104 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171106 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20191105 Year of fee payment: 12 |